MedPath

A phase I/II trial of preoperative chemoradiotherapy with gemcitabine in patients with pancreatic cancer and impaired renal functio

Not Applicable
Conditions
Patients with resectable pancreatic cancer and impaired renal function
Registration Number
JPRN-UMIN000016877
Lead Sponsor
Clinical Study Group of Osaka University
Brief Summary

Refer to paper

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
8
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Unresectable pancreatic cancer (2) Dialysis patients (3)Presence or past history of interstitial pneumonia or pulmonary fibrosis or possible (4) Active infections (excluding viral hepatitis) (5) Severe cardiac disorder, renal disorder, liver disorder, ulcer with bleeding, intestinal tract paralysis, uncontrollable diabetes mellitus (6) Presence of pleural effusion or ascites requiring drainage (7) Presence of metastasis in central nervous system (8) Active double cancer except carcinoma in situ or intramucosal cancer (synchronous double cancer or asynchronous double cancer with disease-free duration to be within 3 years) (9) Pregnant females or nursing mothers who can not stop lactation. Patients or partners, who don't attempt to doing contraception during the study period. (10) Severe mental disorder (11) Severe drug hypersensitivity (12) As determined by the principal investigator or the sub-investigator the subject is not adequate to participate in the trial.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath